PNC-27 Research Peptide Overview
PNC-27 is a synthetic 32-amino acid chimeric peptide built from two functionally distinct domains: an HDM-2 binding region corresponding to residues 12–26 of the p53 tumor suppressor protein, and a C-terminal cell penetrating sequence derived from the antennapedia penetratin domain. The peptide has been found to kill cancer cells, but not normal cells, by inducing membranolysis, making it a selective and well characterized tool for oncology and membrane biology research.
PNC-27 was designed to mimic a specific region of p53, particularly the area involved in binding to HDM-2, a regulatory protein speculated to support p53 stability. In many transformed cell types, HDM-2 (also known as MDM2) is aberrantly expressed at the plasma membrane surface, a feature largely absent in untransformed cells and one that appears central to PNC-27's selectivity in experimental models.
HDM-2 membrane targeting: The selective cytotoxic pore forming effect of PNC-27 is linked to elevated expression of cell surface HDM-2 compared with only low or undetectable levels in the membranes of untransformed cells, and its colocalization with HDM-2 in cancer cell membranes.
Transmembrane pore formation: PNC-27 kills cancer cells by binding to HDM-2 associated with the plasma membrane and induces the formation of pores causing tumor cell lysis and necrosis. Immuno scanning electron microscopy studies have identified PNC-27 and HDM-2 colocalizing in approximately 1:1 ratios within ring shaped pore structures at the cancer cell surface.
Necrotic cell death, not apoptosis: PNC-27 possibly induces a necrosis-like mode of cell death linked to membrane permeabilization rather than apoptosis, with studies reporting LDH release and near complete loss of cell viability without activation of classical caspase dependent markers.
p53-independent activity: PNC-27 binds to HDM-2 expressed in the cancer cell membranes of solid tissue tumor cells and induces transmembrane pore formation in cancer, but not in normal cells, resulting in tumor cell necrosis that is independent of p53 activity. This has been demonstrated in p53-null cell lines, broadening its utility as a research tool beyond tumors with intact p53.
Analytical Validation, Formulation, and Storage
Formulation: Lyophilized powder for reconstitution with an appropriate aqueous solvent, supplied without dosing instructions of any kind.
Storage follows standard peptide handling practice:
Store lyophilized vials at or below −20 °C in a cool, dark, dry environment.
After reconstitution, refrigerate at 2–8 °C, avoid repeated freeze-thaw cycles, and use within laboratory-defined timeframes.
NextGenPeps supplies PNC-27 as a high-purity research peptide intended strictly for controlled laboratory use in vitro or in established animal models. This compound is not approved as a drug, diagnostic, or dietary ingredient in this context, and is not manufactured, packaged, or marketed for consumption, self-experimentation, clinical application, or any use outside properly designed and ethically approved research protocols.